Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 2, 2005, Pages 156-162

  Mallon, Patrick W G ^a,b   Wand, Handan ^a   Law, Matthew ^a   Miller, John ^c   Cooper, David A ^a,b   Carr, Andrew ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c Roche Products Pty Ltd   (Australia)

Author keywords

Antiretroviral therapy; Buffalo hump; HIV; Hypertension; Insulin resistance; Leptin; Lipodystrophy

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; C REACTIVE PROTEIN; DIDANOSINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LACTIC ACID; LAMIVUDINE; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; AGE; ARTICLE; AUSTRALIA; BODY COMPOSITION; BODY MASS; BUFFALO HUMP; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIMB FAT; LIPOATROPHY; LIPODYSTROPHY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RISK FACTOR; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

ADULT; BODY COMPOSITION; CASE-CONTROL STUDIES; CERVICAL VERTEBRAE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPERINSULINISM; HYPERLIPIDEMIAS; INSULIN; LIPIDS; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 13244284831     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000147527.64863.1a     Document Type: Article

References (27)

1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(Suppl):F51-F58.
2. Renard E, Fabre J, Paris F, et al. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf). 1999;51:223-230.
3. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS. 2000;14(Suppl):F25-F32.
4. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Clin Infect Dis. 2000;31:1482-1487.
5. Heath K, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS. 2001;15:231-240.
6. Lichtenstein KA, Ward DJ, Moorman AC, et al. HIV Outpatient Study Investigators. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
7. Paton NI, Earnest A, Ng YM, et al. Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: prevalence, associated factors, and psychological impact. Clin Infect Dis. 2002;35:1244-1249.
8. Saves M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405.
9. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2002;31:50-55.
10. Mallon PWG, Miller J, Cooper D, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1 infected men starting therapy. AIDS. 2003;17:971-979.
11. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
12. Lo JC, Mulligan K, Tai VW, et al. "Buffalo hump" in men with HIV-1 infection. Lancet. 1998;351:867-870.
13. Saint-Marc T, Touraine JL. "Buffalo hump" in HIV-1 infection. Lancet. 1998;352:319-320.
14. Palella FJ, Jr, Cole SR, Chmiel JS, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis. 2004;38:903-907.
15. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
16. Carr A, Emery S, Law M, et al. HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
17. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet. 1999;353:2893-2899.
18. Hengel RL, Watts NB, Lennox JL. Multiple symmetrical lipomatosis associated with protease inhibitors. Lancet. 1997;350:1596.
19. Deleted in proof.
20. Deleted in proof.
21. Wagenknecht LE, Langefeld CD, Scherzinger AL, et al. Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003;52:2490-2496.
22. Passaro A, Calzoni F, Zamboni PF, et al. Role of diabetes in influencing leptin concentration in elderly overweight patients. Eur J Endocrinol. 2001;145:173-179.
23. Hou L, Harshbarger T, Herrick MK, et al. Suprasellar adrenocorticotropic hormone-secreting ectopic pituitary adenoma: case report and literature review. Neurosurgery. 2002;50:618-625.
24. Lin RC, Wang WY, Morris BJ. High penetrance, overweight, and glucocorticoid receptor variant: case-control study. BMJ. 1999;319:1337-1338.
25. Dobson MG, Redfern CP, Unwin N, et al. The N363S polymorphism of the glucocorticoid receptor: potential contribution to central obesity in men and lack of association with other risk factors for coronary heart disease and diabetes mellitus. J Clin Endocrinol Metab. 2001;86:2270-2274.
26. Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379-391.
27. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86:3480-3487.